Funding for this research was provided by:
This work was supported by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) through an unrestricted grant provided by Sanofi [no grant number is applicable].
Received: 12 May 2021
Revised: 22 October 2021
Accepted: 9 November 2021
First Online: 22 December 2021
: MAGE reports other from ROCHE, other from MYLAN, other from SERVIER, other from AMGEN, other from MERCK, other from BAYER, outside the submitted work. MJOM reports personal fees and non-financial support from ROCHE, personal fees and non-financial support from AMGEN, personal fees from SERVIER, personal fees from SANOFI, outside the submitted work. MVA reports grants and personal fees from ROCHE, personal fees from MERCK, personal fees from AMGEN, personal fees from SANOFI, during the conduct of the study; personal fees from SERVIER, personal fees from BAYER, personal fees from CELGENE, outside the submitted work. MS reports grants from AMGEN, grants from MERCK, grants from CELGENE, grants from SERVIER, grants from ROVI, grants from BMS, grants from LEOPHARMA, grants from ROCHE, grants from MYLAN, grants from KHERM PHARMA, outside the submitted work. EMC reports having acted as a speaker for SANOFI. JT reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Taiho, Tessa Therapeutics and TheraMyc. And also the educational collaboration with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). JT also declares institutional financial interest in form of financial support for clinical trials or contracted research for Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Janssen-Cilag SA, MedImmune, Menarini, Merck Health KGAA, Merck Sharp & Dohme, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc, Spanish Association Against Cancer Scientific Foundation and Cancer Research UK. MCR reports personal fees and non-financial support from ROCHE, non-financial support from AMGEN, personal fees from NOVARTIS, non-financial support from SERVIER, personal fees and non-financial support from BAYER, personal fees and non-financial support from MERCK, outside the submitted work. EA reports honoraria for the advisory roles from AMGEN, BAYER, CELGENE, MERCK, ROCHE, SANOFI. The remaining authors declare no competing interests.
: The study was conducted according to the Helsinki Declaration and national regulations. It was approved by the ethics committee of Hospital Reina Sofía (Córdoba, Spain; approval number/ID: 255) and patients gave their written informed consent before taking part.
: Not applicable.